Medexus Pharmaceuticals Inc MEDXF

Primary Symbol: T.MDP

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.

TSX:MDP - Post by User

Medexus Pharmaceuticals Inc > Ebitda Sector Multiple

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Aug 04, 2023 1:06pm

146 Views

Post# 35573651

Ebitda Sector Multiple

Approximately 13 times for this sector..

https://firstpagesage.com/business/pharmaceutical-company-valuation-ebitda-multiples/

Trailing, MDP had $16.1 million US in Ebitda in 2022 which is about $21 million in CAD equivalent to a fair value of about $275 million CAD or about $13 per share.

MDP had Ebitda of $4,8 million US in Q4 of 2022 on $28 m in Revenur

Projecting forward for 2023, this would be about $24 million CAD or about $310 million market cap.

That would be about $15 per share assuming no growth in 2023.

As the revenue for Q1 of 2023 is already known to be in excess of $31 million US, $15 per share may be conservative .

So, another peer based valuation shows tremendous upside here,l